Trial Profile
Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Developed Cooperatively by YunNan Walvax Biotechnology Co., Lt and Yuxi Walvax Biotechnology Co., Lt Among 2-71 Months (the Youngest Could be 6 Weeks) Healthy Infants and Toddlers by Randomized Blind Method With Similar Control in Multi-centers.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs 13 valent Pneumococcal polysaccharide conjugate vaccine Walvax Biotechnology (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors Walvax Biotechnology
- 11 Oct 2020 Status changed from not yet recruiting to completed.
- 16 Apr 2016 New trial record